Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Feb;3(1):113–121. doi: 10.1111/j.1365-2125.1976.tb00578.x

Preliminary assessment of flutiorex, a new anorectic drug, in man.

J F Giudicelli, C Richer, A Berdeaux
PMCID: PMC1428817  PMID: 788737

Abstract

1 The effects of +/--flutiorex, a new anorectic agent, on food intake, the sympathetic nervous system and the central nervous system were compared to those of fenfluramine and a placebo in a double-blind trial involving six healthy volunteers. 2. Flutiorex exerts a singificant anorectic effect and was shown to be approximately twice as potent as fenfluramine in this regard. 3 Flutiorex induces a definite alpha-adrenergic sympathomimetic stimulation as was shown by a rise in systolic blood pressure and the development of marked mydriasis. 4 Flutiorex is a central nervous system stimulant producing an increase in critical flicker frequency. It does not, however, influence psychomotor coordination as reflected in the pursuit rotor test. 5 Serial determinations of blood and urine levels of flutiorex and its deethylated metabolite, norflutiorex, showed that flutiorex is rapidly absorbed and deethylated, accumulates in large quantities in the tissues and, like its metabolite, is excreted in the urine in very small quantities. Blood levels of norflutiorex appear to remain elevated longer than those fo flutiorex.

Full text

PDF
113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckett A. H., Brookes L. G. The absorption and urinary excretion in man of fenfluramine and its main metabolite. J Pharm Pharmacol. 1967 Dec;19(Suppl):42S–49S. [PubMed] [Google Scholar]
  2. Beckett A. H., Coutts R. T., Ogunbona F. A. Metabolism of amphetamines. Identification of N-oxygenated products by gas chromatography and mass spectrometry. J Pharm Pharmacol. 1973 Sep;25(9):708–717. doi: 10.1111/j.2042-7158.1973.tb10052.x. [DOI] [PubMed] [Google Scholar]
  3. Campbell D. B. Gas chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma, red cells and urine following therapeutic doses. J Chromatogr. 1970 Jun 24;49(3):442–447. doi: 10.1016/s0021-9673(00)93657-4. [DOI] [PubMed] [Google Scholar]
  4. Hill R. C., Turner P. Fenfluramine and critical flicker frequency. J Pharm Pharmacol. 1967 May;19(5):337–338. doi: 10.1111/j.2042-7158.1967.tb08098.x. [DOI] [PubMed] [Google Scholar]
  5. Houghton G. W., Latham A. N., Richens A. Difference in the central actions of phenytoin and phenobarbitone in man, measured by critical flicker fusion threshold. Eur J Clin Pharmacol. 1973 Jun;6(1):57–60. doi: 10.1007/BF00561802. [DOI] [PubMed] [Google Scholar]
  6. Kramer R., Rubicek M., Turner P. The role of norfenfluramine in fenfluramine-induced mydriasis. J Pharm Pharmacol. 1973 Jul;25(7):575–576. doi: 10.1111/j.2042-7158.1973.tb09161.x. [DOI] [PubMed] [Google Scholar]
  7. Smart J. V., Sneddon J. M., Turner P. A comparison of the effects of chlorphentermine, diethylpropion and phenmetrazine on critical flicker frequency. Br J Pharmacol Chemother. 1967 Jun;30(2):307–316. doi: 10.1111/j.1476-5381.1967.tb02137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES